Comparative study of hormone receptor status and HER2 expression between primary and recurrent breast cancer.

PURPOSE Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy. We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy. PATIENTS AND METHODS Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy. Estrogen receptor (ER) and progesterone receptor (PR) status was determined immunohistochemically from histologically representative formalin-fixed paraffin-embedded tumor samples. ER status was ascertained by mRNA in situ hybridization. RESULTS Thirty-five (70%) of 50 primary tumors were positive for ER and 30 (60%) for PR. Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%). Discordant cases were due to the loss of ER (n = 6), loss of PR (n = 6), or loss of both receptors (n = 6). Receptor-negative primary tumors were always accompanied by receptor-negative recurrences. Among 27 patients with ER-positive primary tumors, loss of ER was a significant predictor (P = .0085) of poor response to subsequent endocrine therapy. Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression. CONCLUSION Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients. We conclude that analysis of recurrent tumor samples may improve the predictive value of ER and PR assays.

Download Full-text

ER, PR & HER2 Receptor status in recurrent breast cancer: Its relation to age & time of recurrence

Journal of Surgical Sciences ◽

10.3329/jss.v22i1.44009 ◽

2020 ◽

Vol 22 (1) ◽

pp. 16-20

Author(s):

Abu Khaled Muhammad Iqbal ◽

Nasima Akhter ◽

Hasan Shahrear Ahmed ◽

Md Rassell ◽

AMM Yahia ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Approach ◽

Recurrent Breast Cancer ◽

Breast Cancer Patients ◽

Her2 Receptor ◽

Younger Patients ◽

Receptor Status ◽

Increased Risk ◽

Neoplastic Lesions ◽

Recurrent Breast

Background: Malignant neoplastic lesions of the breast are one of the main causes of cancer death among women. In tumor cells the expression status of Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers affecting the treatment approach, management and prognosis of breast carcinoma. Objective: To explore the relation of receptor status in recurrent breast cancer to age and time of recurrence. Methods: This study was conducted in National Institute of Cancer Research and Hospital (NICRH) and included 81 female patients between 20 to 75 years with recurrent breast cancer. Detection of receptor status of ER +ve/-ve, PR +ve/-ve, Her-2+ve/-ve was based on the immunohistochemistry staining of tissue samples of malignant neoplastic lesions prepared from tissue biopsies of patients with recurrent breast cancer. All the information were recorded through the pre-structured data collection sheet and analyzed. Results: This study showed that most of the recurrent breast cancer patients were Triple negative breast cancer (TNBC) (39.5%) and among them most of them were younger patients. Younger patients with TNBC had increased risk of recurrence. Most of the recurrence occurred within 1-2 years. Conclusion: It can be concluded that the assessment of the expression of these biornarkers in recurrent tumors provides reliable information for the treatment approach of locoregional tumors. Journal of Surgical Sciences (2018) Vol. 22 (1): 16-20

Download Full-text

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

Obstetrics and Gynecology ◽

10.1097/01.aog.0000139789.22888.66 ◽

2004 ◽

Vol 104 (3) ◽

pp. 627

Keyword(s):

Breast Cancer ◽

Breast Cancer Risk ◽

Cancer Risk ◽

Hormone Receptor ◽

Hormone Receptor Status ◽

Receptor Status

Download Full-text

Hormone receptor status in primary breast cancer—time for a consensus?

European Journal of Cancer ◽

10.1016/s0959-8049(01)00304-5 ◽

2002 ◽

Vol 38 (9) ◽

pp. 1201-1203 ◽

Cited By ~ 15

Author(s):

G.C Wishart ◽

M Gaston ◽

A.A Poultsidis ◽

A.D Purushotham

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Primary Breast Cancer ◽

Hormone Receptor Status ◽

Receptor Status

Download Full-text

A STUDY ON HORMONE RECEPTOR STATUS IN BREAST CANCER IN RELATION TO HISTOLOGICAL GRADING, AGE AND LYMPH NODE INVOLVEMENT

10.36106/ijar/1601400 ◽

2021 ◽

pp. 41-44

Author(s):

R. Rani Suganya ◽

M. Annapoorani ◽

C. Naveen Kumar

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Hormone Receptor ◽

Histological Grade ◽

Systemic Disease ◽

Lymph Node Involvement ◽

Hormone Receptor Status ◽

Major Health Problem ◽

Receptor Status ◽

Node Involvement

Breast cancer is the major health problem for the women throughout the world.Management of breast cancer has evolved to include both surgery for local disease and medical therapy for systemic disease. Multiple treatment options are available depending on various factors such as histological grade, hormone receptor status etc. The aim of this study is to correlate the hormone receptor status with prognostic factors such as lymph node involvement, tumour grading and age among patients diagnosed with breast cancer in our institution. The results of this study serve to prognosticate the severity of disease among various strata of patients.

Download Full-text